HK1214134A1 - 醋酸格拉替雷的透粘膜给药 - Google Patents

醋酸格拉替雷的透粘膜给药 Download PDF

Info

Publication number
HK1214134A1
HK1214134A1 HK16102020.2A HK16102020A HK1214134A1 HK 1214134 A1 HK1214134 A1 HK 1214134A1 HK 16102020 A HK16102020 A HK 16102020A HK 1214134 A1 HK1214134 A1 HK 1214134A1
Authority
HK
Hong Kong
Prior art keywords
tablet
oral tablet
amount
present
weight
Prior art date
Application number
HK16102020.2A
Other languages
English (en)
Chinese (zh)
Inventor
Geister Ursula
Schweizer Stephan
Buerger Martina
Stefan Ralph
Huber Gerald
Pries Tanja
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1214134A1 publication Critical patent/HK1214134A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16102020.2A 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药 HK1214134A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
HK1214134A1 true HK1214134A1 (zh) 2016-07-22

Family

ID=50979257

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102020.2A HK1214134A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药
HK16102544.9A HK1214523A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102544.9A HK1214523A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Country Status (15)

Country Link
US (1) US20160193276A1 (OSRAM)
EP (1) EP2934492A4 (OSRAM)
JP (1) JP2016503803A (OSRAM)
KR (1) KR20150111918A (OSRAM)
CN (1) CN104869983A (OSRAM)
AU (1) AU2013361053A1 (OSRAM)
BR (1) BR112015014095A2 (OSRAM)
CA (1) CA2895359A1 (OSRAM)
EA (1) EA201591188A1 (OSRAM)
HK (2) HK1214134A1 (OSRAM)
IL (1) IL239280A0 (OSRAM)
MX (1) MX2015007678A (OSRAM)
SG (1) SG11201504422XA (OSRAM)
WO (1) WO2014100639A1 (OSRAM)
ZA (1) ZA201505049B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) * 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
CN108601737A (zh) * 2016-02-12 2018-09-28 特华制药株式会社 干法制粒物和含有该干法制粒物的固态制剂及它的制造方法
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522799A (ja) * 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー１の経口、経鼻および経肺投与製剤
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
AU2002320360B2 (en) * 2001-07-10 2005-05-26 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2623018A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
EP2934492A4 (en) 2016-08-17
AU2013361053A1 (en) 2015-07-30
KR20150111918A (ko) 2015-10-06
IL239280A0 (en) 2015-07-30
CA2895359A1 (en) 2014-06-26
BR112015014095A2 (pt) 2017-07-11
HK1214523A1 (zh) 2016-07-29
WO2014100639A1 (en) 2014-06-26
ZA201505049B (en) 2016-10-26
EP2934492A1 (en) 2015-10-28
US20160193276A1 (en) 2016-07-07
CN104869983A (zh) 2015-08-26
EA201591188A1 (ru) 2016-04-29
SG11201504422XA (en) 2015-07-30
JP2016503803A (ja) 2016-02-08
MX2015007678A (es) 2015-09-07

Similar Documents

Publication Publication Date Title
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
CN104812378B (zh) 固体剂型
ES2862573T3 (es) Formulaciones de nalbufina de liberación sostenida
ES2898348T3 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
US20160193276A1 (en) Transmucosal delivery of glatiramer acetate
TW200815048A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
WO2005115345A1 (en) Oral therapeutic compound delivery system
JP2016535778A (ja) 乱用抑止性剤形
WO2016081676A1 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
KR102669683B1 (ko) 장세척을 위한 경구용 고형제제
CN101784263A (zh) 奈韦拉平的延长释放制剂
WO2004066981A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
EP1567124A1 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
US20040127541A1 (en) Bicifadine formulation
CN1658898A (zh) 包含培哚普利的口腔分散药物组合物
US20110021542A1 (en) Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder
US20050281873A1 (en) Universal controlled-release composition
KR20170086053A (ko) 디메틸 푸마르산염을 포함하는 제약학적 매트릭스 제제
US20190099368A1 (en) Chewable dosage forms containing sitagliptin and metformin
US20160310434A1 (en) Gastro-retentive oral pharmaceutical compositions
WO2019018338A1 (en) NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER
US11096890B2 (en) Chewable dosage forms containing sitagliptin and metformin